Although critical to commercial success, market access remains one of the pharmaceutical industry’s greatest challenges. Following regulatory approval by Health Canada, market access professionals must navigate the complex pricing and reimbursement landscape to ensure therapies are publicly and privately available at a price that is affordable, yet supports continued innovation. The industry will soon be facing new challenges when the Patented Medicine Prices Review Board (PMPRB) updates its 30-year old regulatory framework, intending to lower drug prices for Canadians. This session will provide insight into emerging trends in market access, current challenges and opportunities, and the impact of proposed changes to the PMPRB.
Highlight emerging trends in the Canadian market access and reimbursement environment.
Profile the proposed changes to the PMPRB framework and the potential impact on
patients, payers, and sponsors.
Explore the challenges and opportunities in delivering both value and timely access to
cutting-edge medicines to all Canadians.
Host: Bruce Seet, Ph.D, MBA
With Guest Panelists:
Bennett Lee (Head, Market Access, Sanofi Genzyme)
Joan McCormick (Principal, Price Regulation Consulting, IQVIA)
Alex Chambers (Director, pan-Canadian Oncology Drug Review [pCODR])